413 related articles for article (PubMed ID: 32183871)
1. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.
Yoon DH; Cao J; Chen TY; Izutsu K; Kim SJ; Kwong YL; Lin TY; Thye LS; Xu B; Yang DH; Kim WS
J Hematol Oncol; 2020 Mar; 13(1):21. PubMed ID: 32183871
[TBL] [Abstract][Full Text] [Related]
2. [Treatment for mantle cell lymphoma].
Izutsu K
Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
[TBL] [Abstract][Full Text] [Related]
3. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
[TBL] [Abstract][Full Text] [Related]
4. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
5. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
6. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
7. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
8. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
9. Update on mantle cell lymphoma.
Maddocks K
Blood; 2018 Oct; 132(16):1647-1656. PubMed ID: 30154113
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
11. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
Zaja F; Federico M; Vitolo U; Zinzani PL
Leuk Lymphoma; 2014 May; 55(5):988-98. PubMed ID: 23865835
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
13. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.
Mussetti A; Kumar A; Dahi PB; Perales MA; Sauter CS
Blood Rev; 2015 May; 29(3):143-52. PubMed ID: 25468719
[TBL] [Abstract][Full Text] [Related]
14. Role of allogeneic stem cell transplantation in mantle cell lymphoma.
Cohen JB; Burns LJ; Bachanova V
Eur J Haematol; 2015 Apr; 94(4):290-7. PubMed ID: 25154430
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
16. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies in mantle cell lymphoma.
Maddocks K; Blum KA
Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
19. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
20. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
